Formosa Reports Top-Line Data from P-III (CPN-303) Study of APP13007 for Inflammation and Pain Post Cataract Surgery in Chinese Patients
Shots:
- Formosa has reported topline data from the P-III (CPN-303) trial (conducted by Grand Pharma) of APP13007 (GPN00833) vs PBO to treat inflammation & pain post cataract surgery in Chinese patients (n=255)
- APP13007 eyedrops (BID for 14 days) achieved 1EPs, depicting ACC count = 0 in 31.8% vs 20% of them on POD8 through POD15, with 91.2% vs 55.3% free of ocular pain on POD4 through POD15. Treatment was well-tolerated with safety similar to PBO
- APP13007 is an ophthalmic nanosuspension formulation of clobetasol propionate (0.05%) that is already introduced in the US for the same indication. Additionally, Grand Pharma received exclusive rights to commercialize it across Mainland China, Hong Kong & Macau in 2021
Ref: Formosa | Image: Formosa
Related News:- Formosa Entered into a License Agreement with Eyenovia to Commercialize APP13007 for Inflammation and Pain Following Ocular Surgery
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
